These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 22623153)
1. Diverse monoclonal antibodies against the CA 19-9 antigen show variation in binding specificity with consequences for clinical interpretation. Partyka K; Maupin KA; Brand RE; Haab BB Proteomics; 2012 Jul; 12(13):2212-20. PubMed ID: 22623153 [TBL] [Abstract][Full Text] [Related]
2. Glycan motif profiling reveals plasma sialyl-lewis x elevations in pancreatic cancers that are negative for sialyl-lewis A. Tang H; Singh S; Partyka K; Kletter D; Hsueh P; Yadav J; Ensink E; Bern M; Hostetter G; Hartman D; Huang Y; Brand RE; Haab BB Mol Cell Proteomics; 2015 May; 14(5):1323-33. PubMed ID: 25733690 [TBL] [Abstract][Full Text] [Related]
3. Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers. Yue T; Maupin KA; Fallon B; Li L; Partyka K; Anderson MA; Brenner DE; Kaul K; Zeh H; Moser AJ; Simeone DM; Feng Z; Brand RE; Haab BB PLoS One; 2011; 6(12):e29180. PubMed ID: 22220206 [TBL] [Abstract][Full Text] [Related]
4. Discovery of sialyl Lewis A and Lewis X modified protein cancer biomarkers using high density antibody arrays. Rho JH; Mead JR; Wright WS; Brenner DE; Stave JW; Gildersleeve JC; Lampe PD J Proteomics; 2014 Jan; 96():291-9. PubMed ID: 24185138 [TBL] [Abstract][Full Text] [Related]
5. Summary report on the ISOBM TD-6 workshop: analysis of 20 monoclonal antibodies against Sialyl Lewisa and related antigens. Montreux, Switzerland, September 19-24, 1997. Rye PD; Bovin NV; Vlasova EV; Molodyk AA; Baryshnikov A; Kreutz FT; Garinther WI; Schultes BC; Noujaim AA; Madiyalakan R; Magnani J; Nilsson O; Nilsson K; Nustad K; Norum L; Bell H; Cao Y; Suresh MR; Very DL; Freeman JV; Yeung KK; Hilgers J Tumour Biol; 1998; 19(5):390-420. PubMed ID: 9701730 [TBL] [Abstract][Full Text] [Related]
6. Epitope analysis of SPan-1 and DUPAN-2 using synthesized glycoconjugates sialyllact-N-fucopentaose II and sialyllact-N-tetraose. Kawa S; Tokoo M; Oguchi H; Furuta S; Homma T; Hasegawa Y; Ogata H; Sakata K Pancreas; 1994 Nov; 9(6):692-7. PubMed ID: 7531332 [TBL] [Abstract][Full Text] [Related]
7. Identification of blood-protein carriers of the CA 19-9 antigen and characterization of prevalence in pancreatic diseases. Yue T; Partyka K; Maupin KA; Hurley M; Andrews P; Kaul K; Moser AJ; Zeh H; Brand RE; Haab BB Proteomics; 2011 Sep; 11(18):3665-74. PubMed ID: 21751362 [TBL] [Abstract][Full Text] [Related]
8. Sialyl Lewis(a) ganglioside in pancreatic cancer tissue correlates with the serum CA 19-9 level. Hamanaka Y; Hamanaka S; Suzuki M Pancreas; 1996 Aug; 13(2):160-5. PubMed ID: 8829184 [TBL] [Abstract][Full Text] [Related]
9. Definitive Characterization of CA 19-9 in Resectable Pancreatic Cancer Using a Reference Set of Serum and Plasma Specimens. Haab BB; Huang Y; Balasenthil S; Partyka K; Tang H; Anderson M; Allen P; Sasson A; Zeh H; Kaul K; Kletter D; Ge S; Bern M; Kwon R; Blasutig I; Srivastava S; Frazier ML; Sen S; Hollingsworth MA; Rinaudo JA; Killary AM; Brand RE PLoS One; 2015; 10(10):e0139049. PubMed ID: 26431551 [TBL] [Abstract][Full Text] [Related]
10. Distinct sub-populations of carcinoma-associated MUC1 mucins as detected by the monoclonal antibody 9H8 and antibodies against the sialyl-Lewis a and sialyl-Lewis x epitopes in the circulation of breast-cancer patients. Sikut R; Zhang K; Baeckström D; Hansson GC Int J Cancer; 1996 May; 66(5):617-23. PubMed ID: 8647622 [TBL] [Abstract][Full Text] [Related]
11. Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer. Lohrmann C; O'Reilly EM; O'Donoghue JA; Pandit-Taskar N; Carrasquillo JA; Lyashchenko SK; Ruan S; Teng R; Scholz W; Maffuid PW; Lewis JS; Weber WA Clin Cancer Res; 2019 Dec; 25(23):7014-7023. PubMed ID: 31540979 [TBL] [Abstract][Full Text] [Related]
12. Validation of N-glycan markers that improve the performance of CA19-9 in pancreatic cancer. Zhao YP; Zhou PT; Ji WP; Wang H; Fang M; Wang MM; Yin YP; Jin G; Gao CF Clin Exp Med; 2017 Feb; 17(1):9-18. PubMed ID: 26714469 [TBL] [Abstract][Full Text] [Related]
13. Upregulation of glycans containing 3' fucose in a subset of pancreatic cancers uncovered using fusion-tagged lectins. Singh S; Pal K; Yadav J; Tang H; Partyka K; Kletter D; Hsueh P; Ensink E; Kc B; Hostetter G; Xu HE; Bern M; Smith DF; Mehta AS; Brand R; Melcher K; Haab BB J Proteome Res; 2015 Jun; 14(6):2594-605. PubMed ID: 25938165 [TBL] [Abstract][Full Text] [Related]
14. Role of tumour markers, cytogenetics. Lamerz R Ann Oncol; 1999; 10 Suppl 4():145-9. PubMed ID: 10436809 [TBL] [Abstract][Full Text] [Related]